Abstract:We read with great interest the article by Onuma et al. [1] which evaluated the long-term safety and efficacy of ABSORB bioasorbable everolimus-eluting stent (BVS) scaffold. The investigators of the study have made pioneering contributions to the assessment of bioresorbable scaffolds. It was concluded that sustained safety could be achieved after the implantation of a fully bioresorbable Absorb everolimus-eluting scalffold with a low event rate at 5 years. Besides, the ABSORB Cohort A trial confirmed the feasibility of noninvasive anatomic and functional assessment of the scaffold with the use of multislice computed tomography (MSCT) angiography and MSCT-based fractional flow reserve (FFR) assessment. However, we have several concerns with regard to the study. First, we have to notice that noninvasive FFR analysis was feasible only in 13 patients. The limited size has weakened the reliability of noninvasive FFR performance in assessing functional outcome of ABSORB BVS. Good image quality of all coronary arteries and accurate lumen boundary descriptions are essential for the noninvasive FFR interpretation [2]. Although published reports suggested that CT derived FFR (FFRCT) accuracy was less affected by MSCT image quality than CT stenosis [3], there were four patients (22.2%) who cannot have FFRCT analysis due to severe artifact. Besides, in those with feasible FFRCT, numerous artifacts including calcification, motion, and misregistration may also affect MSCT performance and lead to inaccurate anatomic models for FFRCT computation [4]. Thus, the feasibility and precision of FFRCT need to be further improved. It is not appropriate to use FFRCT alone as a hemodynamic parameter in functional coronary stenosis measurement. Second, a fly in the ointment of the study was the absence of invasive FFR as a reference against noninvasive FFRCT at 5 years. Despite Onuma et al. demonstrated several reasons that they decided to perform repeat MSCT alone instead of invasive imaging, we cannot deny the fact that no published convincing trial exists for FFRCT in the evaluation of interventional treatment [4], although the DISCOVER-FLOW study [5] validated that the FFRCT had a good correlation with an invasive FFR, and the DeFACTO trial [6] demonstrated that the FFRCT plus CT was superior to CT alone as a measure of coronary computed tomography angiography (CCTA) stenosis severity for determination of lesion-specific ischemia. Finally, in the study, angiographic reference standard of the vessel lumen area was derived from MSCT analysis instead of invasive coronary angiography [1]. It is important, however, to note that there is an overestimation of stenosis severity identified by CCTA and even among severe stenosis confirmed by invasive coronary angiography, only a minority cause ischemia [4,6]. Therefore, the possible deviation resulted from the inaccurate reference of MSCT may make the results less convincible.

Long-term Outcome of Intravascular Ultrasound Application in Patients with Moderate Coronary Lesions and Grey-Zone Fractional Flow Reserve.

Physiology- or Imaging-Guided Strategies for Intermediate Coronary Stenosis.

Fractional Flow Reserve or Intravascular Ultrasound for PCI.

Clinical Outcomes of Deferred Lesions by IVUS Versus FFR-Guided Treatment Decision.

Discordance Between Angiographic Assessment and Fractional Flow Reserve or Intravascular Ultrasound in Intermediate Coronary Lesions: A Post-hoc Analysis of the FLAVOUR Trial.

Clinical Outcomes of Deferred Lesions with Angiographically Insignificant Stenosis but Low Fractional Flow Reserve.

2-Year Outcomes of Angiographic Quantitative Flow Ratio-Guided Coronary Interventions.

Comparison of Fractional FLow Reserve and Intravascular Ultrasound-Guided Intervention Strategy for Clinical OUtcomes in Patients with InteRmediate Stenosis (FLAVOUR): Rationale and Design of a Randomized Clinical Trial

Challenges in Multislice Computed Tomography Based Fractional Flow Reserve to Evaluate Interventional Treatment

Angiographic Findings and Post-Percutaneous Coronary Intervention Fractional Flow Reserve

The Potential Safety of Deferring Percutaneous Coronary Intervention Based on Fractional Flow Reserve in the Ischemia-Induced Intermediate Lesions Defined by Intravascular Ultrasound

Mid-Term Clinical Outcomes Of Functionally-Guided Treatment Of Coronary Bifurcation Lesions

Diagnostic performance of intravascular ultrasound-based fractional flow reserve in evaluating of intermediate left main stenosis

Fractional flow reserve versus intravascular imaging to guide decision-making for percutaneous coronary intervention in intermediate lesions: A meta-analysis

Application of Intravascular Ultrasound on Diagnosis and Treatment in Patients With Coronary Artery Intermediate Lesions

Prognostic Implications of Quantitative Flow Ratio and Plaque Characteristics in Intravascular Ultrasound–Guided Treatment Strategy

Long-term Prognostic Value of Dynamic Function Assessment of Intermediate Coronary Lesion with Computational Physiology.

Intravascular Ultrasound-Guided Clinical Decision-Making for Intermediate Coronary Stenosis

Outcomes of Functionally Complete vs Incomplete Revascularization Insights From the FAVOR III China Trial

Intravascular Ultrasound Guidance Improves the Long-term Prognosis in Patients with Unprotected Left Main Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

Optical Flow Ratio From Co-Registration of Coronary Angiography and Optical Coherence Tomography for Predicting Stenting Result and Physiological Significance of Residual Disease